Logo image
Genital warts treatment: beyond imiquimod
Journal article   Peer reviewed

Genital warts treatment: beyond imiquimod

J Yuan, Guoying Ni, Tianfang Wang, Kate E Mounsey, Shelley F Cavezza, Xuan Pan and Xiao Song Liu
Human Vaccines & Immunotherapeutics, Vol.14(7), pp.1815-1819
2018
url
https://doi.org/10.1080/21645515.2018.1445947View
Published Version

Abstract

genital warts imiquimod early protein 7 interleukin 10
Genital warts are one of the most common sexually transmitted diseases worldwide. The disease is a result of infection with low-risk types of human papillomaviruses, mostly type 6 and 11. Current therapies for genital warts are mainly ablative, or alternatively topical application of imiquimod cream and sinecatechin (polyphenon E) ointment to the warts. However, low patient compliance and high recurrence rate are significant problems for the treatment of genital warts by imiquimod and ablative therapies. We summarise recent literature in this area and propose combining imiquimod with other therapies to increase the efficacy of imiquimod.

Details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Web Of Science research areas
Biotechnology & Applied Microbiology
Immunology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#5 Gender Equality

Source: InCites

Logo image